Human papillomavirus (HPV) prevalence and type distribution, and HPV-associated cytological abnormalities in anal specimens from men infected with HIV who have sex with men. 2010

Audrey Damay, and Jaqueline Fabre, and Valérie Costes, and Jean-Michel Didelot, and Marie-Noëlle Didelot, and Nathalie Boulle, and Michel Segondy
Department of Biology and Pathology, Montpellier University Hospital, Montpellier, France.

Human papillomavirus (HPV) detection and typing using the PapilloCheck test and cytological examination were carried out in anal samples collected from 67 men seropositive for human immunodeficiency virus (HIV) who have sex with men. Fifty (74.6%) patients had anal HPV infection, 46 (68.7%) had high-risk (HR) HPV infection, and 38 (56.7%) had multiple infection involving 2-9 (median, 3) HPV types. The HPV types identified most frequently were HPV 44/55 (19.4%), HPV 53 (19.4%), HPV 16 (16.4%), HPV 39 (16.4%), and HPV 42 (14.9%). Thirty-two of the 66 interpretable smears (48.5%) revealed cytological abnormalities: 9 (13.4%) atypical cells of undetermined significance, 20 (30.3%) low-grade intraepithelial lesions, and 3 (4.5%) high-grade intraepithelial lesions. Cytological abnormalities were associated significantly with HPV detection (P < 0.001), multiple HPV infection (P < 0.001), and increased number of HPV types (P < 0.001). The HPV types associated most frequently with cytological abnormalities were HPV 39 (28.1%), HPV 42 (28.1%), HPV 53 (28.1%), HPV 16 (25.0%), HPV 44/55 (25.0%), and HPV 59 (21.9%). HPV DNA detection as well as cytological abnormalities were associated neither with HIV RNA detection in plasma nor with CD4+ T-cell count. Differences in age or in time since HIV acquisition were not observed in patients with or without cytological abnormalities. The present study confirms the high prevalence of anal HR-HPV infection and cytological abnormalities in men infected with HIV who have sex with men. HPV testing and/or cytological analysis may be helpful in selecting the patients to be referred to proctological examination.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003585 Cell Biology The study of the structure, behavior, growth, reproduction, and pathology of cells; and the function and chemistry of cellular components. Cellular Biology,Biologies, Cell,Biologies, Cellular,Biology, Cell,Biology, Cellular,Cell Biologies,Cellular Biologies
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001003 Anal Canal The terminal segment of the LARGE INTESTINE, beginning from the ampulla of the RECTUM and ending at the anus. Anal Gland, Human,Anal Sphincter,Anus,Anal Gland,Anal Glands, Human,Detrusor External Sphincter,External Anal Sphincter,Internal Anal Sphincter,Anal Sphincter, External,Anal Sphincter, Internal,Anal Sphincters,Detrusor External Sphincters,External Anal Sphincters,Human Anal Gland,Human Anal Glands,Internal Anal Sphincters,Sphincter, Anal,Sphincter, Detrusor External,Sphincter, External Anal,Sphincter, Internal Anal,Sphincters, Anal
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences

Related Publications

Audrey Damay, and Jaqueline Fabre, and Valérie Costes, and Jean-Michel Didelot, and Marie-Noëlle Didelot, and Nathalie Boulle, and Michel Segondy
September 2013, Diseases of the colon and rectum,
Audrey Damay, and Jaqueline Fabre, and Valérie Costes, and Jean-Michel Didelot, and Marie-Noëlle Didelot, and Nathalie Boulle, and Michel Segondy
January 2014, Journal of the International AIDS Society,
Audrey Damay, and Jaqueline Fabre, and Valérie Costes, and Jean-Michel Didelot, and Marie-Noëlle Didelot, and Nathalie Boulle, and Michel Segondy
April 2009, Current opinion in infectious diseases,
Audrey Damay, and Jaqueline Fabre, and Valérie Costes, and Jean-Michel Didelot, and Marie-Noëlle Didelot, and Nathalie Boulle, and Michel Segondy
February 2018, Journal of medical virology,
Audrey Damay, and Jaqueline Fabre, and Valérie Costes, and Jean-Michel Didelot, and Marie-Noëlle Didelot, and Nathalie Boulle, and Michel Segondy
November 2013, Journal of clinical microbiology,
Audrey Damay, and Jaqueline Fabre, and Valérie Costes, and Jean-Michel Didelot, and Marie-Noëlle Didelot, and Nathalie Boulle, and Michel Segondy
January 2020, Oral diseases,
Audrey Damay, and Jaqueline Fabre, and Valérie Costes, and Jean-Michel Didelot, and Marie-Noëlle Didelot, and Nathalie Boulle, and Michel Segondy
October 2018, Future microbiology,
Audrey Damay, and Jaqueline Fabre, and Valérie Costes, and Jean-Michel Didelot, and Marie-Noëlle Didelot, and Nathalie Boulle, and Michel Segondy
June 2009, AIDS (London, England),
Audrey Damay, and Jaqueline Fabre, and Valérie Costes, and Jean-Michel Didelot, and Marie-Noëlle Didelot, and Nathalie Boulle, and Michel Segondy
December 2012, BMC infectious diseases,
Audrey Damay, and Jaqueline Fabre, and Valérie Costes, and Jean-Michel Didelot, and Marie-Noëlle Didelot, and Nathalie Boulle, and Michel Segondy
February 2016, LGBT health,
Copied contents to your clipboard!